European Commission Decision expected Q3 2021
Temporary Authorization for Use (ATU) Granted in France to Allow Access and Reimbursement of Vosoritide to Begin Immediately
Vosoritide is Potentially the First Medicine to be Approved to Treat Children with Achondroplasia in Europe
Estimated Over 11,000 Children Across Europe, Middle East, and Africa Affected by Achondroplasia and Eligible for Treatment if Approved
FDA Review of Vosoritide NDA Ongoing, PDUFA Target Action Date Nov. 20, 2021
PR Newswire
SAN RAFAEL, Calif., June 25, 2021